Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

• Revenue in USD (TTM)112.53m
• Net income in USD-261.57m
• Incorporated2013
• Employees226.00

• Location
  Rhythm Pharmaceuticals Inc222 Berkeley Street, 12th Floor BostonBOSTON 02116United StatesUSA
• Phone+1 (857) 264-4280
• Fax+1 (857) 264-4299
• Websitehttp://www.rhythmtx.com